ArticlePloS one2026
Identification of divergent PTPN11 mutations in canine histiocytic sarcomas reveals evidence of an independent clonal origin.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHistiocytic sarcoma (HS) is a rare but highly aggressive neoplasm in humans, with limited knowledge on indicators markers and no standardized treatment. Dogs naturally develop HS, offering a powerful comparative model. Activating mutations in PTPN11, affecting two recurrent hotspots (E76 and G503), are the most frequent drivers of canine HS and are strongly associated with the disseminated form (DHS). While DHS is typically considered metastatic, we hypothesize that multiple independent tumor clones may arise within the same individual.
methodsWe investigated clonal heterogeneity in 38 dogs affected with DHS presenting tumors in both abdominal and thoracic organs. PTPN11 hotspot mutations were analyzed by high-sensitivity droplet digital PCR (ddPCR) to detect low-abundance variants. The frequency of divergent mutations between tumor sites was used to infer the proportion of cases arising from independent clonal origins.
resultsDivergent PTPN11 mutations were directly observed in 3 of 28 dogs with PTPN11-mutated tumor pairs. After correcting for the limited detectability inherent to hotspot-based analysis, we estimated that, in this cohort, up to 24-45% of DHS cases may harbor clonally independent PTPN11 mutations in distinct tumors. In addition, analysis of somatic mutations and copy number variants by Next Generation Sequencing (NGS) in two cell lines derived from the same patient confirmed the independent origin of the clones.
conclusionsOur findings suggest that a significant numbers of dogs with DHS develop several genetically distinct HS lesions either simultaneously or within a short time interval. This need to be confirmed in larger cohorts but this clonal diversity challenges the assumption that DHS is predominantly metastatic and has major implications for prognosis, therapeutic strategies, and the use of canine HS as a comparative model for human disease. Further exploration of clonal evolution in HS is warranted to improve treatment approaches in both species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.